IQVIA (NYSE:IQV) Stock Rating Upgraded by StockNews.com

IQVIA (NYSE:IQV) was upgraded by equities researchers at StockNews.com from a “hold” rating to a “buy” rating in a note issued to investors on Wednesday.

IQV has been the subject of several other research reports. Robert W. Baird reduced their price objective on shares of IQVIA from $256.00 to $223.00 and set a “neutral” rating for the company in a research note on Friday, November 1st. Evercore ISI reduced their price target on IQVIA from $270.00 to $265.00 and set an “outperform” rating for the company in a report on Tuesday, October 8th. The Goldman Sachs Group dropped their price target on IQVIA from $280.00 to $250.00 and set a “buy” rating on the stock in a research note on Friday, November 1st. Leerink Partners restated an “outperform” rating and set a $248.00 price objective (down from $260.00) on shares of IQVIA in a research report on Tuesday. Finally, Barclays lowered their price objective on IQVIA from $260.00 to $255.00 and set an “overweight” rating for the company in a research note on Friday, November 1st. Four equities research analysts have rated the stock with a hold rating, fifteen have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $256.50.

IQVIA Stock Up 1.6 %

IQV traded up $3.05 during midday trading on Wednesday, reaching $194.38. 2,600,478 shares of the company were exchanged, compared to its average volume of 1,167,403. IQVIA has a one year low of $187.62 and a one year high of $261.73. The company has a debt-to-equity ratio of 1.76, a quick ratio of 0.81 and a current ratio of 0.81. The company’s fifty day moving average price is $224.22 and its 200 day moving average price is $227.56. The company has a market cap of $35.28 billion, a price-to-earnings ratio of 25.51, a price-to-earnings-growth ratio of 1.98 and a beta of 1.51.

Insider Buying and Selling at IQVIA

In other IQVIA news, insider Eric Sherbet sold 1,300 shares of IQVIA stock in a transaction dated Tuesday, August 27th. The stock was sold at an average price of $246.33, for a total value of $320,229.00. Following the transaction, the insider now owns 19,536 shares in the company, valued at $4,812,302.88. The trade was a 6.24 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Corporate insiders own 1.60% of the company’s stock.

Institutional Investors Weigh In On IQVIA

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Capital Performance Advisors LLP purchased a new stake in shares of IQVIA during the third quarter worth $27,000. Park Place Capital Corp purchased a new stake in IQVIA in the third quarter worth about $28,000. Versant Capital Management Inc increased its position in shares of IQVIA by 733.3% during the second quarter. Versant Capital Management Inc now owns 125 shares of the medical research company’s stock valued at $26,000 after acquiring an additional 110 shares in the last quarter. Opal Wealth Advisors LLC bought a new position in IQVIA during the second quarter valued at approximately $27,000. Finally, Itau Unibanco Holding S.A. purchased a new position in shares of IQVIA in the second quarter worth approximately $29,000. 89.62% of the stock is owned by institutional investors.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.